1990 graduated from the Department of Microbiology of Shandong University, and 1994 went to the United States after receiving his Ph.D. in Microbiology from China Academy of Sciences. He worked as a postdoctoral researcher in the Department of Pharmacology, Emory University, Atlanta, USA, and was promoted to assistant professor. It is found for the first time in the world that the apoptotic kinase ASK 1 is closely related to the signal transduction protein 14-3-3 which regulates the cancer process. From 1999 to 2003, he worked as a senior scientist and director of new drug research and development department in Microbia, Inc and Cetek, Inc in the United States, respectively, and built a high-quality sample library of microbial natural products for new drug research and development, and isolated and screened a variety of drug lead compounds. For the first time in the world, the new genetic engineering method was successfully used to increase the yield of lovastatin, a lipid-lowering drug produced by medicinal fungus A.terrus, to 2.5 times that of the existing industrial bacteria, and facilitated the post-extraction process. In 2004, he founded SynerZ Interactive Pharmaceutical Company and served as the chairman. He has edited or participated in the compilation of 6 academic monographs (including 3 English versions), obtained the authorization of 1 1 international patent invention, published more than 60 papers in PNAS and other magazines, and made meetings and invited reports at relevant international academic conferences for many times. He is a reviewer of nine magazines such as PNAS, and has been the editor of the international academic journal Applied Microbiology and Biotechnology and the editorial board of the Journal of Antibiotics for a long time.